| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/07/2006 | EP1663395A1 Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent |
| 06/07/2006 | EP1663343A2 Application of a therapeutic substance to a tissue location using an expandable medical device |
| 06/07/2006 | EP1663339A1 Endoluminal prosthesis comprising a therapeutic agent |
| 06/07/2006 | EP1663333A2 Bone cement compositions having fiber-reinforcement and/or increased flowability |
| 06/07/2006 | EP1663318A1 A radioisotope-chitosan complex for treatment of prostate cancer |
| 06/07/2006 | EP1663314A2 Pharmaceutical products comprising bisphosphonates |
| 06/07/2006 | EP1663313A2 Compositions useful for treating gastrointestinal motility disorders |
| 06/07/2006 | EP1663312A1 Anti cancer combinations comprising a cox-2 inhibitor |
| 06/07/2006 | EP1663311A2 Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 06/07/2006 | EP1663310A1 Pharmaceutical composition for preventing or remedying cardiac hypertrophy and cardiocascular disease caused thereby |
| 06/07/2006 | EP1663299A2 Methods for preventing neurological events |
| 06/07/2006 | EP1663291A2 Recombinant lubricin molecules and uses thereof |
| 06/07/2006 | EP1663283A1 Glutamine for use in treating injury |
| 06/07/2006 | EP1663273A1 Powdery composition for use as a laxative |
| 06/07/2006 | EP1663266A1 Yeast cell walls for the treatment or prevention of hyperglycemia or for the stabilisation of glycemia |
| 06/07/2006 | EP1663265A1 Bacteriophage-containing therapeutic agents |
| 06/07/2006 | EP1663261A2 Purified polyoxypropylene/polyoxyethylene copolymers and method of preparing the same |
| 06/07/2006 | EP1663260A1 Chemotherapeutic antineoplastic treatment |
| 06/07/2006 | EP1663259A2 Compositions and methods for treatment of cancer |
| 06/07/2006 | EP1663258A2 Pharmaceutical compositions and therapeutic treatment with oligo-beta- (1,3) - glucans |
| 06/07/2006 | EP1663257A1 Method for treating irritable bowel syndrome using laxatives |
| 06/07/2006 | EP1663256A1 Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome |
| 06/07/2006 | EP1663255A2 Withanamide and withanolide compositions and method of use thereof |
| 06/07/2006 | EP1663254A2 Anti-inflamatory phosphonate conjugates |
| 06/07/2006 | EP1663253A2 Formulations and methods of treating inflammatory bowel disease |
| 06/07/2006 | EP1663252A1 Application assembly for medicaments that are to be applied to the skin and packaging that is used as an application assembly |
| 06/07/2006 | EP1663251A1 Use of 2-methylene-19-nor-20(s)-1a,25-dihydroxyvitamin d3 to increase the life expectancy of human beings |
| 06/07/2006 | EP1663250A1 Methods for treating bladder dysfunction |
| 06/07/2006 | EP1663249A1 1,3-DIACLYATED,26,27-ALKYL/HALOALKYL VITAMIN D sb 3 /sb COMPOUNDS AND METHODS OF USE THEREOF |
| 06/07/2006 | EP1663247A2 Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep |
| 06/07/2006 | EP1663246A2 Use of the sgk gene family for diagnosis and therapy of cataracts and glaucoma |
| 06/07/2006 | EP1663245A1 Cephem compounds |
| 06/07/2006 | EP1663244A2 Pteridine derivatives for the treatment of septic shock and tnf-alpha-related diseases. |
| 06/07/2006 | EP1663243A1 Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer |
| 06/07/2006 | EP1663242A2 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| 06/07/2006 | EP1663241A1 5-arylpyrimidines as anticancer agents |
| 06/07/2006 | EP1663240A1 Combinations of a pyrimidine containing nnrti with rt inhibitors |
| 06/07/2006 | EP1663239A2 Potassium channel mediated delivery of agents through the blood-brain barrier |
| 06/07/2006 | EP1663238A1 HEXA- AND OCTAHYDRO-PYRIDO[1,2-a] PYRAZINE DERIVATIVES WITH NK1 ANTAGONISTIC ACTIVITY |
| 06/07/2006 | EP1663236A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-¬1,3,4-oxadiazol-2-yl| phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a biphosphonate |
| 06/07/2006 | EP1663235A1 Capped pyrazinoylguanidine sodium channel blockers |
| 06/07/2006 | EP1663233A1 Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis |
| 06/07/2006 | EP1663232A1 1-(2-amino-benzoyl)-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| 06/07/2006 | EP1663231A1 Oral itraconazole composition which is not affected by ingested food and process for preparing same |
| 06/07/2006 | EP1663230A1 Compositions comprising benzo(g)quinoline derivatives and prostaglandin derivatives |
| 06/07/2006 | EP1663229A2 Pharmaceutical combinations of hydrocodone and naltrexone |
| 06/07/2006 | EP1663228A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 06/07/2006 | EP1663227A2 Dihydropyridine compounds for treating or preventing metabolic disorders |
| 06/07/2006 | EP1663226A1 Pharmaceutical compositions of moxifloxacin and processes for their preparation |
| 06/07/2006 | EP1663225A1 Compositions for veterinary and medical applications |
| 06/07/2006 | EP1663224A1 A pharmaceutical composition comprising a p2x7 receptor antagonist and a nonsteroidal anti inflammatory drug |
| 06/07/2006 | EP1663222A1 Methods related to the treatment of mucosal associated conditions |
| 06/07/2006 | EP1663221A1 Ophthalmic compositions for treating ocular hypertension |
| 06/07/2006 | EP1663220A1 Novel process, salts, compositions and use |
| 06/07/2006 | EP1663219A2 Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process |
| 06/07/2006 | EP1663218A1 Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| 06/07/2006 | EP1663217A1 Solid dispersions comprising tacrolimus |
| 06/07/2006 | EP1663216A1 Modified release compositions comprising tacrolimus |
| 06/07/2006 | EP1663215A1 Novel medical use of selective cb1- receptor antagonists |
| 06/07/2006 | EP1663214A1 Cancer treatment with epothilones |
| 06/07/2006 | EP1663213A1 Substituted oxadiazolidinediones as pai-1 inhibitors |
| 06/07/2006 | EP1663212A1 Solid dosage formulation containing a factor xa inhibitor and method |
| 06/07/2006 | EP1663209A1 Novel orally administered dosage form for 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-ethyl proprionate and salts thereof |
| 06/07/2006 | EP1663208A1 Use of telmisartan for the prevention of vascular headache |
| 06/07/2006 | EP1663207A2 NOVEL METHODS FOR IDENTIFYING IMPROVED, NON-SEDATING a-2 AGON ISTS |
| 06/07/2006 | EP1663206A1 Nonsedating a-2 agonist 1-(2,3-dimethyl-phenyl)-ethyl-1,3-dihydro-imidazole-2-thione |
| 06/07/2006 | EP1663205A1 Use of 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| 06/07/2006 | EP1663204A2 C-kit modulators and methods of use |
| 06/07/2006 | EP1663203A1 Pharmaceutical compositions for the treatment of organophosphate poisoning |
| 06/07/2006 | EP1663202A1 Substituted indoles as inhibitors of poly (adp-ribose) polymerase (parp) |
| 06/07/2006 | EP1663201A1 A use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same |
| 06/07/2006 | EP1663200A2 Combination therapy for glycaemic control |
| 06/07/2006 | EP1663199A1 Compositions and methods using same for treating amyloid-associated diseases |
| 06/07/2006 | EP1663198A1 Pharmaceutical formulations of xanthogenates and inhibitors of viral nucleic acid replication (e.g. aciclovir) |
| 06/07/2006 | EP1663197A1 The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| 06/07/2006 | EP1663196A2 Methods and products which utilize n-acyl-l-aspartic acid |
| 06/07/2006 | EP1663195A2 Taurine bromamine for inhibiting pathogenic bacteria and fungi growth as well as in a microbicidal composition |
| 06/07/2006 | EP1663194A2 Method of treating cancer with hdac inhibitors |
| 06/07/2006 | EP1663193A1 Sulfonamide derivatives for the treatment of diabetes |
| 06/07/2006 | EP1663192A1 Erg channel openers for the treatment of cardiac arrhythmias |
| 06/07/2006 | EP1663189A1 4-(phenyl-ethylideneaminoxy-propoxy)-phenyl-acetic acid derivatives and related compounds as pai-1 inhibitors for the treatment of impairement of the fibrinolytic system and of thrombisis |
| 06/07/2006 | EP1663188A2 Treatment of disorders of the nervous system |
| 06/07/2006 | EP1663187A2 Antiflatulents in combination with histamine h1-receptor antagonists for treating gastrointestinal disorders |
| 06/07/2006 | EP1663186A2 Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound |
| 06/07/2006 | EP1663185A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss |
| 06/07/2006 | EP1663183A2 Solid pharmaceutical dosage form |
| 06/07/2006 | EP1663182A1 Rapid dissolution formulation of a calcium receptor-active compound |
| 06/07/2006 | EP1663181A2 Protein binding compounds |
| 06/07/2006 | EP1663180A1 Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation |
| 06/07/2006 | EP1663174A1 Single unit pharmaceutical composition comprising a mixture of a fibrate and a homocysteine reducing agent |
| 06/07/2006 | EP1663173A1 Enteric soft gelatin capsule containing esomeprazole and method of preparation |
| 06/07/2006 | EP1663170A1 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 06/07/2006 | EP1663168A2 Nicotine formulations and use thereof |
| 06/07/2006 | EP1663167A1 Dosage forms with an enterically coated core tablet |
| 06/07/2006 | EP1663166A2 Sustained release dosage forms of ziprasidone |
| 06/07/2006 | EP1663164A2 Methods for preparing pharmaceutical compositions |
| 06/07/2006 | EP1663161A2 Slow release estradiol-progesterone formulation for contraception and hormone replacement therapy |
| 06/07/2006 | EP1663160A2 Melt-formulated, multi-particulate oral dosage form |
| 06/07/2006 | EP1663159A2 Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| 06/07/2006 | EP1663157A2 Stabilized formulations of phosphatidylserine |